Vorinostat
Overview
Vorinostat, also known as suberoylanilide hydroxamic acid (SAHA), is an HDAC inhibitor used in cancer treatment. It is approved for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma.
API suppliers (1)
Suppliers of Vorinostat evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
- MYLAN LABORATORIES LTD GMP on record
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Vorinostat expires 18 Mar 2028. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Vorinostat? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.